News for 'US Food and Drug Administration'

FSSAI launches probe into MDH and Everest products

FSSAI launches probe into MDH and Everest products

Rediff.com23 Apr 2024

The Food Safety and Standards Authority of India (FSSAI) has commissioned a quality check on MDH and Everest products. This follows complaints that several popular spice mixes of the two leading brands contained traces of ethylene oxide more than the permissible levels, official sources said. This move by FSSAI comes after Hong Kong and Singapore recalled variants of the two masala majors' products in their countries.

CDSCO panel recommends anti-Covid pill Molnupiravir for emergency use

CDSCO panel recommends anti-Covid pill Molnupiravir for emergency use

Rediff.com28 Dec 2021

The emergency use of the drug will be for adult COVID-19 patients with SpO2 93 percent and who have a high risk of progression of the disease including hospitalisation or death subject to certain conditions

Maha cancels Johnson & Johnson's baby powder manufacturing licence

Maha cancels Johnson & Johnson's baby powder manufacturing licence

Rediff.com17 Sep 2022

Samples of the powder for babies did not conform to standard pH value during a laboratory test, the regulator said.

Dr Reddy's launches insomnia drug in US; Glenmark gets FDA nod

Dr Reddy's launches insomnia drug in US; Glenmark gets FDA nod

Rediff.com16 Apr 2014

Sunovion Pharmaceuticals Inc is the owner of the Eszopiclone drug.

The Coming Dementia Epidemic

The Coming Dementia Epidemic

Rediff.com20 Dec 2024

Around 7.4 per cent of Indians aged 60 and above are affected by dementia. This number is expected to rise from the current 8.8 million to 17 million by 2036, marking a 97 per cent increase.

Drug regulator to make routine inspection of Chinese suppliers

Drug regulator to make routine inspection of Chinese suppliers

Rediff.com15 Nov 2013

Move follows a spate of international regulatory enforcements on Indian drug firms.

US drug regulator warns RPG Life Sciences

US drug regulator warns RPG Life Sciences

Rediff.com19 Jun 2013

The US Food and Drug Administration (USFDA) has issued a warning letter to RPG Life Sciences for violation of current good manufacturing practice (CGMP) norms at its two plants at Ankleshwar and Mumbai.

Anti-malarial drug a 'line of defence' against virus: Trump

Anti-malarial drug a 'line of defence' against virus: Trump

Rediff.com20 May 2020

The US president said the drug has gotten a bad reputation only because 'he was promoting it'.

Ranbaxy recalls 29,790 packs of anti-allergy drug in US

Ranbaxy recalls 29,790 packs of anti-allergy drug in US

Rediff.com2 May 2014

Ranbaxy Laboratories is recalling 29,790 blister packs of anti-allergy drug in the US, manufactured by its arm Ohms Laboratories, due to defective packaging.

USFDA warns Aurobindo Pharma

USFDA warns Aurobindo Pharma

Rediff.com23 May 2011

Company had earlier received an import alert in February this year from the US Food and Drug Administration.

Indian pharma exports to Iran decline thanks to its lower rupee reserves

Indian pharma exports to Iran decline thanks to its lower rupee reserves

Rediff.com3 Oct 2023

India's pharmaceutical exports to Iran have been hit owing to depleting rupee reserves in the West Asian country because of India stopping the import of crude oil from it in 2019 following US sanctions. Pharmaceutical exports dropped 71.25 per cent in April-August this year over the same period last year. The data from the Pharmaceutical Exports Promotion Council (Pharmexcil) showed exports to Iran had declined 31.29 per cent in 2022-23 as against the previous financial year.

Equity market volatility may persist; long-term outlook remains constructive: Experts

Equity market volatility may persist; long-term outlook remains constructive: Experts

Rediff.com3 Apr 2025

The heightened global uncertainty due to the US "reciprocal tariffs" on India may cause near-term corrections and market turbulence, but the long-term outlook remains constructive, market experts said on Thursday. The US has announced 27 per cent reciprocal tariffs on India, citing high import duties imposed by New Delhi on American goods.

'Real growth and opportunity are going to come from GLP-1'

'Real growth and opportunity are going to come from GLP-1'

Rediff.com21 Aug 2024

'It is not just the US and European opportunity, but it is a huge global opportunity.'

Lupin recalls 9,210 bottles of anti-infective drug from the US

Lupin recalls 9,210 bottles of anti-infective drug from the US

Rediff.com15 Apr 2014

The recent recalls come amid increased FDA scrutiny of medicines produced in India.

Taking anti-malarial drug to protect against virus: Trump

Taking anti-malarial drug to protect against virus: Trump

Rediff.com19 May 2020

Soon after Trump revealed to the world that he has been taking the medicine, the White House doctor said the president is in good health.

Post takeover, Sun Pharma to rebrand Ranbaxy drugs in the US

Post takeover, Sun Pharma to rebrand Ranbaxy drugs in the US

Rediff.com9 Apr 2014

Ranbaxy drugs sold in the United States will be gradually rebranded as Sun Pharma treatments

As domestic sales decline, drug makers focus on exports

As domestic sales decline, drug makers focus on exports

Rediff.com1 Oct 2020

While sales in the domestic market declined 4.2 per cent during the April-July period, exports grew steadily at 9.5 per cent during the same period.

Trump warns India of retaliation if it doesn't allow export of drug

Trump warns India of retaliation if it doesn't allow export of drug

Rediff.com7 Apr 2020

The US president said that he has sought help from Prime Minister Narendra Modi to allow the sale of Hydroxychloroquine tablets ordered by the US to treat the growing number of coronavirus patients in his country, hours after India banned the export of the anti-malarial drug.

Notice to ayurvedic drugs firm for misleading Covid claims

Notice to ayurvedic drugs firm for misleading Covid claims

Rediff.com20 Apr 2021

The company claimed that its product is "three times better than remdesivir and that 'AAYUDH Advance starts where vaccines stop'."

Want To Invest In Pharma & Healthcare?

Want To Invest In Pharma & Healthcare?

Rediff.com5 Nov 2024

'A long-term investor with a 4 to 5 year horizon could invest in this theme via SIPs.'

Lupin gets USFDA nod to market HIV drug in US

Lupin gets USFDA nod to market HIV drug in US

Rediff.com10 Dec 2013

The company has received final approval from the US Food and Drug Administration for its Abacavir Sulfate Lamivudine, and Zidovudine Tablets, Lupin Ltd said in a statement.

Be a good neighbour, don't stoke fire of hatred: Manipur slams Mizoram CM

Be a good neighbour, don't stoke fire of hatred: Manipur slams Mizoram CM

Rediff.com30 Nov 2024

The Manipur government has accused Mizoram Chief Minister Lalduhoma of stoking hatred and division through "unwarranted comments" and called on him to display "better statesmanship" by being a "good neighbour". In a statement, the Manipur government alleged that Lalduhoma's comments were part of a "greater agenda" to carve out a Kuki-Chin Christian nation from contiguous areas of Myanmar, India, and Bangladesh. It also warned against any attempt to "push" illegal Kuki-Chin immigrants from Mizoram into Manipur for land grabbing and the creation of a "Greater Mizoram." The Mizoram government could not be reached immediately for comment.

Maha suspends licences of 6 cough syrup manufacturers for rule breach

Maha suspends licences of 6 cough syrup manufacturers for rule breach

Rediff.com4 Mar 2023

Rathod said the Maharashtra government had initiated an inquiry against 84 out of 108 manufacturers of cough syrups in the state.

Trump's tariffs: How will these sectors in India be impacted?

Trump's tariffs: How will these sectors in India be impacted?

Rediff.com2 Apr 2025

Goods from sectors, including agriculture, precious stones, chemicals, pharma, medical devices, electricals, and machinery may get impacted if the US will go ahead with imposing reciprocal tariffs on Indian products, according to experts. They said that these sectors could face additional customs duties from the Trump administration because of the high tariff differential or gap, which is the difference between the import duties imposed by the US and India on a product.

USFDA pulls up Sun Pharma for lapses in Halol plant

USFDA pulls up Sun Pharma for lapses in Halol plant

Rediff.com14 Jan 2023

The US health regulator has pulled up drug major Sun Pharma for manufacturing lapses, including failure to follow appropriate written procedures designed to prevent microbiological contamination of drug products, at its Gujarat-based plant. In a warning letter, the US Food and Drug Administration (USFDA) pointed out various lapses at the Halol plant which produces finished pharmaceutical products. "This warning letter summarises significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals... Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated," the USFDA stated.

USTR Report Intensifies Trade Tensions With India

USTR Report Intensifies Trade Tensions With India

Rediff.com2 Apr 2025

The US Trade Representative noted that India's average applied tariff rate stood at 17% per cent, the highest of any major world economy.

A bitter pill for Aurobindo's sterile drug unit

A bitter pill for Aurobindo's sterile drug unit

Rediff.com25 Nov 2019

USFDA issues Form 483 with as many as 14 observations that could impact ongoing operations at Aurobindo's Pashamailaram facility in Hyderabad.

Pricing challenge in US biz, rich valuations may weigh on pharma stocks

Pricing challenge in US biz, rich valuations may weigh on pharma stocks

Rediff.com11 Jun 2024

The tailwind of low price erosion in the US generics market, seen by domestic pharmaceutical companies in calendar year 2023 (CY23), may be reversing slowly, caution analysts. According to the latest data from US-based Centers for Medicare and Medicaid Services (CMMS), price erosion in calendar year 2024 (CY24) on a year-to-date (YTD) basis stood at a high of 15 per cent in the oral solid dosage (OSD) segment compared to a low of 1 per cent in CY23. This erosion, according to a report by Antique Stock Broking, was the highest in the last three years.

FDA finds contaminated drug ingredient at GSK Ireland plant

FDA finds contaminated drug ingredient at GSK Ireland plant

Rediff.com2 Apr 2014

The FDA has stepped up its efforts to ensure drug safety in recent months.

Govt approves 2 new vaccines, Covid drug for emergency use

Govt approves 2 new vaccines, Covid drug for emergency use

Rediff.com28 Dec 2021

The announcement comes a day after the Subject Expert Committee (SEC) on COVID-19 of the CDSCO recommended granting emergency use authorisation (EUA) to the COVID-19 vaccines Covovax and Corbevax with certain conditions.

Lupin gets USFDA nod for additonal strengths of cholesterol drug

Lupin gets USFDA nod for additonal strengths of cholesterol drug

Rediff.com22 Oct 2013

The company has received final approval for its supplemental New Drug Application (sNDA) for Antara (Fenofibrate) capsules in 30 mg and 90 mg strengths from the United States Food and Drug Administration (USFDA), Lupin Ltd said in a statement.

3 Indian pharma cos recall products in US market

3 Indian pharma cos recall products in US market

Rediff.com24 Apr 2022

Leading drug firms Aurobindo Pharma, Sun Pharma and Jubilant are recalling different products in the US market for various reasons, as per the latest enforcement report by the US Food and Drug Administration (USFDA). While Aurobindo Pharma is recalling Cyanocobalamin Injection, which is used to treat and prevent lack of vitamin B12, Mumbai-based Sun Pharma is recalling a drug used to increase the production of natural tears in eyes. Similarly, Jubilant Cadista is recalling a drug which is used to treat different inflammatory conditions.

Maggi issue: Will food regulator move the Supreme Court?

Maggi issue: Will food regulator move the Supreme Court?

Rediff.com18 Aug 2015

The court had provided a conditional relief to Nestle India.

Kejriwal stopped taking insulin before his arrest: Tihar officials

Kejriwal stopped taking insulin before his arrest: Tihar officials

Rediff.com20 Apr 2024

The Delhi minister also claimed that Kejriwal used to take 50 units of insulin daily before he was sent to jail.

Sun Pharma's Halol facility listed under USFDA import alert

Sun Pharma's Halol facility listed under USFDA import alert

Rediff.com8 Dec 2022

Sun Pharmaceutical Industries Ltd on Thursday said its Halol facility in Gujarat has been listed under import alert by the USFDA with products manufactured at the unit now are subject to refusal of admission in the US market. The development follows an inspection of the facility by the US Food and Drug Administration (USFDA) from April 26 to May 9, 2022. "We now wish to inform you that the company has received a communication from the USFDA stating that the facility has been listed under Import Alert," Sun Pharma said in a regulatory filing.

Less competition, demand-supply gap push US drug prices

Less competition, demand-supply gap push US drug prices

Rediff.com13 Oct 2014

Competition in the US pharmaceutical market swelled in recent years, with increasing generic penetration.

Under the lens: Regulator moots pre-export govt testing for cough syrup cos

Under the lens: Regulator moots pre-export govt testing for cough syrup cos

Rediff.com24 May 2023

After reports of contamination in cough syrups sent from the country, India is considering a system to test them before exporting. It is learnt that the Central Drugs Standard Control Organisation (CDSCO) has sent a proposal to the Union health ministry on this. The idea is to test the medicines at government labs before exporting.

Covovax as Covid booster jab to be available on CoWIN soon

Covovax as Covid booster jab to be available on CoWIN soon

Rediff.com10 Apr 2023

Covovax is likely to be available on the portal in a few days at a price of Rs 225 per dose plus applicable GST.

Ranbaxy sues US FDA for revoking drug approvals

Ranbaxy sues US FDA for revoking drug approvals

Rediff.com18 Nov 2014

FDA had cancelled Ranbaxy's approvals to launch generic Nexium, Valcyte

Sun Pharma's growth pill: Specialising in specialty and scaling in India

Sun Pharma's growth pill: Specialising in specialty and scaling in India

Rediff.com25 Mar 2024

Traction for its specialty portfolio, a strong showing in the domestic market, and better regulatory compliance are positives for the country's largest pharmaceutical (pharma) company, Sun Pharmaceutical Industries. Given the triggers, some brokerages have increased their earnings per share estimates and target price for 2024-25 (FY25). This should sustain the momentum for the stock, which has been one of the major pharma gainers in 2023-24 (FY24), rising 57 per cent. It is currently trading at Rs 1,547 per share.